Mixed Results For Emisphere Trial
A midstage trial of Emisphere Technologies Inc.'s (EMIS) diabetes treatment produced mixed results sending the stock price down $2.11 to close at $6.77.
posted by FC Market News at 10:11 AM
Monday, October 30, 2006
Previous Posts
- Point Therapeutics Reports Positive Results
- Nextest Warns Of Slowdown
- Profit Falls For Georgia Gulf
- Hittite's Forecast Disappoints
- Mannatech Being Investigated
- Volcom's Revenue Rises
- Positive Results For Vertex
- Higher Earnings For Harman International
- Renovis Reports Failed Drug Test
- Oracle Competes Against Red Hat
0 Comments:
Post a Comment
<< Home